Abstract:Objective: Accurate diagnostic assessment of human epidermal growth factor receptor-2 (HER-2) is essential and a prerequisite for appropriate application of the humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin) to the treatment of patients with breast cancer. Immunohistochemistry (IHC) is the most widely applicable diagnostic modality in studying HER-2 status. Fluorescence in situ hybridization (FISH) is also recognized as a modality in cases with an equivocal IHC status (score, 2+). Some authors claimed that FISH alone is sufficient. The aim of this study was to correlate the test results of IHC and FISH for HER-2 gene amplification in breast cancer patients. FISH for topoisomerase IIalpha (TOP2A) was also studied to see if deletion or amplification of TOP2A has any supplementary role to HER-2, FISH and IHC. Materials and methods: Assessment of HER-2 gene amplification and TOP2A gene amplification/deletion was made by FISH analysis using the LSI TOP2A/HER-2/CEP 17 multicolor probe or the LSI HER-2/CEP dual color probe (Vysis, Downers Grove, IL, USA) in formalin-fixed and paraffin-embedded tissue sections of 54 breast cancer patients who were grouped into stages 1+, 2+ or 3+ based on IHC (HercepTest; DakoCytomation, Carpinteria, CA, USA) observations. Results: None of IHC 1+ breast tumors was HER-2 FISH positive, but three of 18 (17%) IHC 3+ tumors were HER-2 FISH negative. Overall, 53% of the IHC 2+ and 83% of the IHC 3+ cases were HER-2 FISH positive. Only one case with IHC 3+ tumor that was HER-2 FISH positive was found to have TOP2A amplification (>2.0) and no IHC 2+ cases were found to have TOP2A amplification. There were no cases with TOP2A deletion (<0.8) in our whole series. There were also no cases of HER-2 FISH negative tumors, but IHC scored as 2+ or 3+ (0 of 10), to be found with TOP2A amplification. The discordance rates by IHC were high (46.7% in IHC 2+, 16.7% in IHC 3+, 30.3% overall in IHC 2+ or 3+). On the contrary, the discordance rates were zero if by FISH. Conclusion: The current algorithm to use HER-2 FISH as a supplementary role to IHC HercepTest 2+ may need some modifications according to the local setting. TOP2A FISH adds little value to HER-2 FISH and IHC staining in our study.

Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: does over-expression exist? And what is its correlation with traditional diagnostic parameters?: Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue

Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: does over-expression exist? And what is its correlation with traditional diagnostic parameters?

Her Family Receptors Expression in Squamous Cell Carcinoma of the Tongue: Study of the Possible Prognostic and Biological Significance

HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases.

A Comparative Study on HER-2 Expression by Immunohistochemistry and Fluorescence in Situ Hybridization in Breast Cancer Tissue

HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).

The Study of C-erbB-2 and Nm23 Protein in Oral Squamous Cell Carcinoma

The Expression and Correlation Analysis of ErbB-2 and ErbB-3 in Tongue Squamous Cell Carcinoma

Comparision of HER2/neu Oncogene Detected by Chromogenic In-Situ Hybridization and Immunohistochemistry in Breast Cancer

Expression of C-erbB-2 Protein in Different Sliding Techniques of Breast Cancer

EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases

Egfr and Her2 Expression in Primary Cervical Cancers and Corresponding Lymph Node Metastases: Implications for Targeted Radiotherapy

Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas

Human Epidermal Growth Factor Receptor 2 Protein Expression Between Primary Breast Cancer and Paired Asynchronous Local-Regional Recurrences.

An Analysis of HER2 Amplification in Cervical Adenocarcinoma: Correlation with Clinical Outcomes and the International Endocervical Adenocarcinoma Criteria and Classification

[Expression of Human Epidermal Growth Factor Receptor 2 in Gastroesophageal Cancer with Different Scoring Systems and Its Relationship with Clinicopathological Features].

HER-2 gene amplification and protein expression in esophageal squamous cell carcinoma

Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients

The Role of c-erbB-2 Expression on the Survival of Patients with Small-Cell Lung Cancer

Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method

Human papillomavirus in carcinomas of the tongue: clinical and prognostic implications